Verastem Oncology (VSTM) shares rallied 22.2% in a month, primarily driven by the FDA approval of the company’s novel combination regimen of avutometinib plus defactinib in early May for treating KRAS mutant recurrent low-grade serous ovarian cancer (LGSOC), a rare and distinct type of ovarian cancer. The FDA's decision came well in advance of the originally expected date of June 30, 2025.The approval was granted under the FDA’s accelerated approval pathway and is commercialized in the U.S. market as an ora ...